"I agree," Huang Jiacai said, "I propose that during the last month of the training camp, we add innovation practice projects. Participants will be grouped to design optimization plans based on the real issues in their countries or regions. We can provide seed funding to support the implentation of the best plan."
This proposal made Yang Ping’s eyes light up; nurturing executors is important, but nurturing changemakers is even more significant.
"How much funding is needed?"
"For the first phase, we’re prepared to provide ten million US dollars. If the effect is good, we can continue," Huang Jiacai said, "This money doesn’t co from Ruixing’s operational funds, instead, it’s drawn from personal funds from myself and several investors, considering it as an investnt for the future."
Yang Ping looked at him and suddenly smiled, "Your style of doing things now doesn’t quite resemble that of a businessman?"
"Even businessn should have ideals; otherwise, no matter how much money you earn, waking up in the middle of the night will feel empty," Huang Jiacai also smiled, "Besides, investing in these young people is investing in K Therapy truly taking root globally, which is more worthwhile than any advertising spend; investors are making the longest-term investnt."
In the hall, participants were grouped in discussion, those doctors from different countries and cultural backgrounds were gathered here because of a technology, now beginning to think about how to better serve their countries and people with this technology.
"Sotis I think," Yang Ping said, "maybe the greatest value of K Therapy is not how many diseases it can cure by itself, but that it acts as a seed, inspiring global healthcare workers to think and pursue a more equitable and effective healthcare system."
...
Three days later, eting Room, Shanghai Huashan Hospital.
Wu Dechang’s plan achieved substantial progress. After Academician Chen Yongnian "switched sides" to support Sanbo, Wu Dechang quickly adjusted his strategy, turning to join a group of mid-generation scientists from Shanghai, initiating the "Open Tumor Targeted Therapy Platform" project.
Today’s eting is the project launch eting, attending were not only scientists, but also representatives from three dostic pharmaceutical companies, and most importantly, two experts from the National Science and Technology Major Project Review Committee.
"Everyone, we’re here today not to replicate K Therapy, but to build an open, iterative tumor-targeted therapy technology platform," Wu Dechang’s opening was very strategic, "The core principles of this platform are: modularization, open-source, collaboration."
Actually, he wanted to replicate K Therapy, using these people to replicate K Therapy.
The screen displayed the platform architecture diagram: the lowest layer is a public knowledge base, including validated tumor marker databases, carrier safety data, preclinical research specifications; the middle layer consists of tool modules, including various virus/non-virus vector construction sches, various pro-apoptotic/immunoactivating gene components, targeting system design tools; the top layer is the application layer, where researchers can assemble different modules like building blocks to create their own treatnt plans.
"All module design plans, safety data, construction thods will be open-source shared," Wu Dechang emphasized, "Any certified research institution can freely use these modules for research and clinical translation. The only condition is: data from the translational results must be fed back into the public knowledge base, forming a positive cycle."
A pharmaceutical company representative asked, "How will intellectual property and comrcial interests be distributed?"
"The intellectual property of application layer results belongs to the R&D team and can be comrcialized. But the foundational modules remain open-source," Wu Dechang said, "It’s like the Android system; Google provides an open-source system, phone manufacturers develop their own products on this basis and profit. We provide an open-source treatnt technology platform, pharmaceutical companies develop specific therapies on this basis."
This analogy helped everyone understand that openness does not an it’s unprofitable, but rather changes the mode of interest distribution.
An expert from the review committee asked, "Is this platform competitive or complentary with Ruixing’s technology path?"
"It should be complentary," Wu Dechang answered craftily, "Ruixing has proven the feasibility of this technology path, they’re like pioneers, paving the way. What we need to do is to widen this path so more can walk on it. Moreover, the open-sourceness of the platform ans Ruixing can also use the platform’s modules to optimize their technology, if they wish."
This positioning is very smart: not as a challenger, but as a supplent; not competition, but ecosystem construction.
Wu Changde wanted to use deception to make a hidden move, and when the ti cos, everything will be out of their control.
User Comments
0 comments from readers